In a regulatory filing, Scholar Rock ( SRRK) CEO Jay Backstrom disclosed the sale of 18,372 common shares of the company on February 18 at a price of $36.829 per share. Published first on TheFly – the ...

CAMBRIDGE, MA—Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44. ...

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...